Biomarker Menu


Download this assay page in pdf format.


GIP (Gastric Inhibitory Polypeptide)

Analyte: Gastric Inhibitory Polypeptide

Specimen Type: Plasma from BD P700 or P800, EDTA Plasma with preservatives; contact PBI for collection instructions

Optimum Volume: 0.5 mL


2-8°C -20°C -70°C
3 hours 3 days 1 year

Reporting units: pmol/L

Method: ELISA

Biological or Clinical Significance:

GIP, also known as gastric inhibitory polypeptide, or glucose-dependent insulinotropic polypeptide, is a 42 amino acid peptide hormone synthesized in and secreted from K cells in the intestinal epithelium. The gut endocrine K cells sense nutrient intake and secret GIP following ingestion of the nutrients, especially fats. Unlike GLP-1, which exerts multiple non-incretin activities in the regulation of blood glucose, the primary action of GIP is the stimulation of glucose-dependent insulin secretion. GIP may also play a role in adipocyte biology and it seems to act to regulate body weight. GIP is rapidly inactivated both in vitro and in vivo by the dipeptidyl peptidase 4 (DPP-4), the enzyme which also cleaves GLP-1 and GLP-2, rapidly inactivates GIP. The majority of circulating GIP immunoreactivity in both the fasting and postprandial states corresponds to the biologically inactive GIP (amino acids 3-42).

Principle of Test Method:

The GIP assay is a solid-phase ELISA designed to measure human GIP in serum and plasma. It employs the quantitative sandwich enzyme immunoassay principle.


1. Hinke SA, Gelling RW, Pederson RA, Manhart S, Nian C, Demuth HU, McIntosh CH. Dipeptidyl Peptidase IV-Resistant [D-Ala2]Glucose- Dependent Insulinotropic Polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes 2002; 51:652-661.
2. Stock S, Leichner P, Wong ACK, Chatei MA, Kieffer TJ, Bloom SR, Chanoine JP. Ghrelin, peptide YY, glucose-dependent instulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. J Clin Endocrinol Metab 2005; 90:2161-2168.
3. Kazakos KA, Sarafidis PA, Yovos JG. The impact of diabetic autonomic neuropathy on the incretin effect. Med Sci Monit 2008;14:CR213-220.
4. Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ. Predictors in incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008; 57:678-687.

Related Assays

Downloadable, Printable Biomarker Menus

Alphabetical Listing

Download PDF

Biomarker Category

Download PDF